Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target cellular messenger RNAs (mRNAs) with seed-region complementarity represent a major class of unintended targets for RNA interference (RNAi) therapeutics, such as small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs). This phenomenon occurs when the 'seed region' of the siRNA guide strand—typically nucleotides 2 through 8—binds to complementary sequences in the 3' untranslated regions (UTRs) of non-target mRNAs (Jackson et al., 2003, Nature Biotechnology). This interaction mimics the natural mechanism of microRNAs (miRNAs), leading to the degradation or translational repression of these unintended transcripts (Birmingham et al., 2006, Nature Methods). Because a single 7-nucleotide seed sequence can be present in hundreds of different cellular mRNAs, a single siRNA can potentially perturb the expression of many genes simultaneously. Such off-target effects are a primary concern in drug safety, as they can lead to cellular toxicity, altered metabolic pathways, or hepatotoxicity in clinical settings (Janas et al., 2018, Nature Communications). To mitigate these risks, researchers employ chemical modifications, such as 2'-O-methyl substitutions at position 2 of the guide strand, to reduce the binding affinity of the seed region while maintaining on-target potency. Understanding and predicting these interactions through bioinformatics and transcriptomic profiling is essential for the design of safe and specific RNA-based medicines.
Seed-mediated RNA interference (RNAi) leading to mRNA degradation or translational repression
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target cellular messenger RNAs with seed-region complementarity.